查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1108406

全球□和抗凝剂市场2018-2028：按管理途径、产品、应用、最终用户和地区划分的趋势分析、竞争市场份额和预测

Global Peptide and Anticoagulant Drugs Market, By Route of Administration, By Product, By Application, By End-User, By Region Trend Analysis, Competitive Market Share & Forecast, 2018-2028
出版日期: | 出版商: Blueweave Consulting | 英文 121 Pages | 商品交期: 2-3个工作天内

价格

预计全球多□和抗凝剂市场规模在预测期内将以 5.4% 的复合年增长率增长，到 2028 年底将达到约 21.5 亿美元。

由于所有人群中慢性病的患病率不断上升，全球多□和抗凝剂市场正在蓬勃发展。缺血性心脏病、静脉血栓栓塞症 (VTE) 发病率上升、对创新口服抗凝剂 (NOAC) 认识的提高以及对早期诊断益处的认识不断提高等因素也在推动市场的增长。

在本报告中，我们调查了全球多□和抗凝剂市场并提供了市场概况，分析了市场增长的各种影响因素、监管环境、技术趋势、市场规模的转变和预测、各种分类和总结按地区/主要国家、竞争环境、市场份额、主要公司概况等细分。

内容

第一章研究框架

第二章研究方法

第 3 章执行摘要

第 4 章全球多□和抗凝剂市场洞察

  • 工业价值链分析
  • DROC 分析
    • 驱动程序
    • 限制因素
    • 机会
    • 任务
  • 技术进步/近期发展
  • 监管框架
  • 波特五力分析

第 5 章全球多□和抗凝剂市场概述

  • 市场规模和预测
  • 市场份额/预测
    • 按给药途径
      • 肠胃外
      • 口语
      • 经粘膜
      • 其他
    • 按产品
      • 荷尔蒙
      • 抗生素
      • ACE抑製剂
      • 抗真菌剂
      • 其他
    • 按用途
      • 糖尿病
      • 感染
      • 癌症
      • 骨质疏鬆症
      • 心脏病
      • 妇科
    • 按最终用户
      • 医院
      • 医务室
      • 家庭护理
      • 其他
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

第 6 章北美□和抗凝剂市场

  • 市场规模和预测
  • 市场份额/预测
    • 按给药途径
    • 按产品
    • 按用途
    • 按最终用户
    • 按国家/地区

第 7 章。欧洲□和抗凝剂市场

  • 市场规模和预测
  • 市场份额/预测
    • 按给药途径
    • 按产品
    • 按用途
    • 按最终用户
    • 按国家/地区

第 8 章亚太□和抗凝剂市场

  • 市场规模和预测
  • 市场份额/预测
    • 按给药途径
    • 按产品
    • 按用途
    • 按最终用户
    • 按国家/地区

第 9 章拉丁美洲□和抗凝剂市场

  • 市场规模和预测
  • 市场份额/预测
    • 按给药途径
    • 按产品
    • 按用途
    • 按最终用户
    • 按国家/地区

第 10 章中东和非洲□和抗凝剂市场

  • 市场规模和预测
  • 市场份额/预测
    • 按给药途径
    • 按产品
    • 按用途
    • 按最终用户
    • 按国家/地区

第 11 章竞争格局

  • 主要公司和产品列表
  • 市场份额分析
  • 竞争基准
  • 重大战略发展（併购/合作）

第 12 章 COVID-19 对全球□和抗凝剂市场的影响

第 13 章公司简介（公司简介、财务矩阵、竞争形势、主要人力资源、主要竞争对手、联繫人、战略展望）

  • F.Hoffmann-La Roche Ltd
  • Mylan
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Pfizer
  • GSK
  • Novartis AG
  • Allergan
  • Eisai Co Ltd
  • Merck & Co Inc
  • 其他有力企业

第14章 主要策略建议

Product Code: BWC22235

Global Peptide and Anticoagulant Drugs Market to Reach USD 2.15 Billion by 2028

Global Peptide and Anticoagulant Drugs Market is flourishing owing to the rising number of cardiovascular diseases and technological advancements along with the emergence of new markets…

A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Peptide and Anticoagulant Drugs Market is projected to grow at a CAGR of 5.4%, earning revenues of around USD 2.15 billion by the end of 2028. The Global Peptide and Anticoagulant Drugs Market is booming because the prevalence of the chronic disease is rising internationally, in every region, and across all socioeconomic strata. Thus, the requirement for efficient therapies is accelerated by the rising prevalence of chronic diseases, which is anticipated to fuel the market for peptide and anticoagulant medications. Moreover, the market for peptides and anticoagulants is predicted to grow as a result of rising rates of ischemic heart disease, venous thromboembolism (VTE), and awareness of innovative oral anticoagulants (NOACs). Furthermore, Global Peptide and Anticoagulant Drugs Market is one of the most emerging markets that grow continuously owing to the rising public awareness of the benefits of early diagnostics. However, the high level of market consolidation and the availability of alternative drugs are impeding the global growth of the Peptide and Anticoagulant Drugs Market.

Increasing Number of Cardiovascular Diseases

Increased prevalence of cardiovascular illnesses encourages further industry growth. Due to the rise in cardiovascular disorders, the industry is expanding. The market is growing mostly as a result of cardiovascular issues. Cardiovascular diseases are the biggest cause of death worldwide, accounting for almost 18.6 million deaths in 2019, according to the Heart Disease and Stroke Statistics Update Fact Sheet published in 2021. Annually, cardiovascular disorders claim more lives than cancer and chronic lower respiratory disease (CLRD) combined. The increased prevalence of chronic diseases in both elderly and middle-aged populations is another factor that is expected to quicken the market's rate of expansion. Additionally, the aging of the world's population is expected to spur growth in the market for peptide and anticoagulant drugs.

Technology Advancement Fuels Market Expansion

Anticoagulant product development technology advances are anticipated to help the market. According to a study that was released in the Frontier in Biotechnology and Bioengineering in December 2019, highly accurate, durable, and affordable anticoagulant products have been created using cutting-edge technologies like microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and micro/nano electromechanical systems (MEMS/NEMS). The market is also growing as a result of a rise in R&D efforts and the emergence of new markets. These elements will create favorable conditions for the market expansion of peptide and anticoagulant medicines.

Challenge: Expensive Drug Development Procedures

The high costs associated with drug development and distribution, on the other hand, will slow the market's growth rate. The lack of healthcare infrastructure in developing economies, as well as a scarcity of skilled professionals, will pose a challenge to the peptide and anticoagulant drug markets. Furthermore, a lack of public awareness and stringent government regulations will restrain and impede the market's growth rate during the forecast period of 2022-2029.

Segmental Coverage

Global Peptide and Anticoagulant Drugs Market - By Product

Based on product, the Global Peptide and Anticoagulant Market is segmented into Hormonal, Antibiotic, ACE Inhibitor, Antifungal, and Others. Among these, the hormonal segment is expected to grow at the fastest rate during the forecast period. During puberty, menstruation, and pregnancy, hormonal imbalances are more common. However, external factors such as stress or hormone medications can cause hormonal imbalances. All these factors boost the growth of the India Brake Pad Market during the forecast period (2022-2028).

Impact of COVID-19 on Global Peptide and Anticoagulant Drugs Market

COVID-19 infection has a significant impact on the peptide and anticoagulant drug markets. More than ten clinical trials are underway to assess the potential of anticoagulants in COVID-19 patients, according to a study published in the American Journal of Cardiovascular Drugs in 2020, and research on parenteral administration strategies for these drugs for use in critically ill COVID-19 patients is being conducted. Furthermore, patients with COVID-19, both confirmed and suspected, should have access to follow-up care with low-dose anticoagulants, according to a World Health Organization Update published in January 2021. As a result, anticoagulant demand skyrocketed during COVID-19.

Competitive Landscape

The leading market players in the Global Peptide and Anticoagulant Drugs Market are F.Hoffmann-La Roche Ltd, Mylan, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer, GSK, Novartis AG, Allergan, Eisai Co Ltd, Merck & Co Inc, and other prominent players. The Global Peptide and Anticoagulant Drugs Market is highly fragmented with the presence of several manufacturing companies in the country. The market leaders retain their supremacy by spending on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Don't miss the business opportunity in the Global Peptide and Anticoagulant Drugs Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Peptide and Anticoagulant Drugs Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Peptide and Anticoagulant Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing both qualitative and quantitative data to boost the performance of your business solutions. BWC has built its reputation from the scratch by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Research
  • 2.2. Quantitative Research
  • 2.3. Market Breakdown & Data Triangulation
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary Research Respondents
  • 2.5. Assumption & Limitation

3. Executive Summary

4. Global Peptide and Anticoagulant Drugs Market Insights

  • 4.1. Industry Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
    • 4.2.4. Challenges
  • 4.3. Technological Advancement/Recent Development
  • 4.4. Regulatory Framework
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Intensity of Rivalry

5. Global Peptide and Anticoagulant Drugs Market Overview

  • 5.1. Market Size & Forecast by Value, 2018-2028
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration
      • 5.2.1.1. Parenteral
      • 5.2.1.2. Oral
      • 5.2.1.3. Mucosal
      • 5.2.1.4. Others
    • 5.2.2. By Product
      • 5.2.2.1. Hormonal
      • 5.2.2.2. Antibiotic
      • 5.2.2.3. ACE Inhibitor
      • 5.2.2.4. Antifungal
      • 5.2.2.5. Others
    • 5.2.3. By Application
      • 5.2.3.1. Diabetes
      • 5.2.3.2. Infectious Product
      • 5.2.3.3. Cancer
      • 5.2.3.4. Osteoporosis
      • 5.2.3.5. Cardiology
      • 5.2.3.6. Gynecology
    • 5.2.4. By End-User
      • 5.2.4.1. Hospitals
      • 5.2.4.2. Clinics
      • 5.2.4.3. Homecare
      • 5.2.4.4. Others
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. Latin America
      • 5.2.5.5. Middle East and Africa

6. North America Peptide and Anticoagulant Drugs Market

  • 6.1. Market Size & Forecast by Value, 2018-2028
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End-User
    • 6.2.5. By Country
      • 6.2.5.1. United States
      • 6.2.5.2. Canada

7. Europe Peptide and Anticoagulant Drugs Market

  • 7.1. Market Size & Forecast by Value, 2018-2028
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End-User
    • 7.2.5. By Country
      • 7.2.5.1. Germany
      • 7.2.5.2. United Kingdom
      • 7.2.5.3. Italy
      • 7.2.5.4. France
      • 7.2.5.5. Spain
      • 7.2.5.6. Rest of Europe

8. The Asia Pacific Peptide and Anticoagulant Drugs Market

  • 8.1. Market Size & Forecast by Value, 2018-2028
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End-User
    • 8.2.5. By Country
      • 8.2.5.1. China
      • 8.2.5.2. India
      • 8.2.5.3. Japan
      • 8.2.5.4. South Korea
      • 8.2.5.5. Rest of Asia Pacific

9. Latin America Peptide and Anticoagulant Drugs Market

  • 9.1. Market Size & Forecast by Value, 2018-2028
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. Brazil
      • 9.2.5.2. Mexico
      • 9.2.5.3. Rest of Latin America

10. The Middle East & Africa Peptide and Anticoagulant Drugs Market

  • 10.1. Market Size & Forecast by Value, 2018-2028
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End-User
    • 10.2.5. By Country
      • 10.2.5.1. Saudi Arabia
      • 10.2.5.2. UAE
      • 10.2.5.3. South Africa
      • 10.2.5.4. Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1. List of Key Players and Their Offerings
  • 11.2. Market Share Analysis, 2021
  • 11.3. Competitive Benchmarking, By Operating Parameters
  • 11.4. Key Strategic Development (Merger, Acquisition, Partnership.)

12. Impact of Covid-19 on Global Peptide and Anticoagulant Drugs Market

13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **

  • 13.1. F.Hoffmann-La Roche Ltd
  • 13.2. Mylan
  • 13.3. Teva Pharmaceutical Industries Ltd
  • 13.4. Sanofi
  • 13.5. Pfizer
  • 13.6. GSK
  • 13.7. Novartis AG
  • 13.8. Allergan
  • 13.9. Eisai Co Ltd
  • 13.10. Merck & Co Inc
  • 13.11. Other Prominent Players

14. Key Strategic Recommendations

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

  • Figure 1: Global Peptide and Anticoagulant Drugs Market Segmentation
  • Figure 2: Global Peptide and Anticoagulant Drugs Market Industry Value Chain Analysis
  • Figure 3: Global Peptide and Anticoagulant Drugs Market Size, By Value (USD Million),2018-2028
  • Figure 4: Global Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 5: Global Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028
  • Figure 6: Global Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028
  • Figure 7: Global Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028
  • Figure 8: Global Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028
  • Figure 9: North America Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028
  • Figure 10: North America Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 11: North America Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028
  • Figure 12: North America Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028
  • Figure 13: North America Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028
  • Figure 14: North America Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028
  • Figure 15: Europe Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028
  • Figure 16: Europe Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 17: Europe Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028
  • Figure 18: Europe Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028
  • Figure 19: Europe Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028
  • Figure 20: Europe Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028
  • Figure 21: Asia-Pacific Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028
  • Figure 22: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 23: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028
  • Figure 24: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028
  • Figure 25: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028
  • Figure 26: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028
  • Figure 27: Latin America Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028
  • Figure 28: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 29: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028
  • Figure 30: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028
  • Figure 31: Latin America Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028
  • Figure 32: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028
  • Figure 33: Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028
  • Figure 34: Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028
  • Figure 35: Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028
  • Figure 36: Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028
  • Figure 37: Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028
  • Figure 38: Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028
  • Figure 39: Global Peptide and Anticoagulant Drugs Market Share Analysis, 2021

List of Tables

  • Table 1: Global Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), 2018-2028
  • Table 2: Global Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028
  • Table 3: Global Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028
  • Table 4: Global Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 5: Global Peptide and Anticoagulant Drugs Market Size. By Country, By Value (USD Million), 2018-2028
  • Table 6: North America Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), 2018-2028
  • Table 7: North America Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028
  • Table 8: North America Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028
  • Table 9: North America Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 10: North America Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028
  • Table 11: Europe Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), By Value 2018-2028
  • Table 12: Europe Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), By Value 2018-2028
  • Table 13: Europe Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), By Value 2018-2028
  • Table 14: Europe Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), By Value 2018-2028
  • Table 15: Europe Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028
  • Table 16: Asia-Pacific Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), By Value 2018-2028
  • Table 17: Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Route of Administration, By Value 2018-2028
  • Table 18: Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Product, By Value 2018-2028
  • Table 19: Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Application, By Value 2018-2028
  • Table 20: Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By End-User, By Value 2018-2028
  • Table 21: Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028
  • Table 22: Latin America Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), By Value 2018-2028
  • Table 23: Latin America Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028
  • Table 24: Latin America Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028
  • Table 25: Latin America Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 26: Latin America Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028
  • Table 27: Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), 2018-2028
  • Table 28: Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028
  • Table 29: Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028
  • Table 30: Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028
  • Table 31: Middle East & Africa Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028
  • Table 32: List of Key Players and Their Offerings
  • Table 33: Competitive Benchmarking, by Operating Parameters
  • Table 34 F.Hoffmann-La Roche Ltd Company Overview
  • Table 35 F.Hoffmann-La Roche Ltd Financial Overview
  • Table 36 Mylan Company Overview
  • Table 37 Mylan Financial Overview
  • Table 38 Teva Pharmaceutical Industries Ltd Company Overview
  • Table 39 Teva Pharmaceutical Industries Ltd Financial Overview
  • Table 40 Sanofi Company Overview
  • Table 41 Sanofi Financial Overview
  • Table 42 Pfizer Company Overview
  • Table 43 Pfizer Financial Overview
  • Table 44 GSK Company Overview
  • Table 45 GSK Financial Overview
  • Table 46 Novartis AG Company Overview
  • Table 47 Novartis AG Financial Overview
  • Table 48 Allergan Company Overview
  • Table 49 Allergan AG Financial Overview
  • Table 50 Eisai Co Ltd Company Overview
  • Table 51 Eisai Co Ltd Financial Overview
  • Table 52 Merck & Co Inc Company Overview
  • Table 53 Merck & Co Inc Financial Overview